Spanish survey on anaemia management;Estudio epidemiológico sobre el tratamiento de la anemia en España

Nefrologia

Volumn 23, Issue 4, 2003, Pages 300-311

  Perez Garcia R ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Anaemia; Dialysis; Erythropoietin; Guidelines

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; FERRITIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIALYSIS; HEALTH SURVEY; HUMAN; PRACTICE GUIDELINE; PREVALENCE; PROSPECTIVE STUDY; REVIEW; ARTICLE; ATTITUDE TO HEALTH; BLOOD; BLOOD PRESSURE MEASUREMENT; CLINICAL PRACTICE; CLINICAL TRIAL; INFORMATION PROCESSING; MULTICENTER STUDY; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; SPAIN; TREATMENT OUTCOME;

ANEMIA; BLOOD PRESSURE DETERMINATION; DATA COLLECTION; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; SPAIN; TREATMENT OUTCOME;

EID: 4544376885     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Valderrábano P: Concluding remarks. Nephrol Dial Transplant 16 (Supl. 2): 19-20, 2001.
2. Portolés J: The beneficial effects of intervention in early renal disease. Nephrol Dial Transplant 16 (Supl. 2): 12-15, 2001.
3. Eckardt KU: The create trial-building the evidence. Nephrol Dial Transplant 16 (Supl. 2): 16-18, 2001.
4. NKF-DOQI Work Group: NKF-DOQI clinical practice guidelines for the treatment of anaemia of chronic renal failure. Am J Kidney Dis 30 (Supl. 3): S192-S240, 1997.
5. European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure: Guideline 14: causes of an inadequate response to epoetin treatment. Nephrol Dial Transplant 14 (Supl. 5): 25-27, 2000.
6. European Survey on Anaemia Management (ESAM): Nephrol Dial Transplant 15 (Supl. 4); 33-42, 2000.
7. Comité de Registro de la SEN y Registros Autonómicos: Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos correspondientes al año 1999. Nefrología 21: 246-252, 2001.
8. Parfrey PS y cols.: The clinical epidemiology of cardiac disease in chronic renal failure. JASN 10: 1606-15, 1999.
9. Foley RN, Parfrey PS: Anemia in predialysis chronic renal failure: what are we treating? J Am Soc Nephrol 9 (Supl. 12): S82-4, 1998.
10. Hayashi T y cols.: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kid Dis 35 (2): 250-56, 2000.
11. Fink J y cols.: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kid Dis 37 (2): 348-55, 2001.
12. Bailie GR, Johnson CA, Mason NA: Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 35: 1-12, 2000.
13. Collins A, Ebben J, Ma J: Frequent IV iron dosing is associated with higher infectious deaths. J Am Soc Nephrol 8: 190A, 1997.
14. Slonen JT, Nyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R: High stored iron levels are associated with excess risk of myocardial infarction in eastern finnish men. Circulation 86: 803-11, 1992.
15. Eschbach JW: Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol 13: 1412-1414, 2002.
16. Sánchez L, Del Pozo C, Torregrosa I, Albero MD, López Menchero R, Ramos JR: Ferroterapia intravenosa en hemodiálisis: comparación de dos pautas de tratamiento. Nefrología 21 (Supl. 2): 40, 2001.
17. Pérez-García R, Rodríguez-Benítez P, Villaverde MT, Valderrábano F: El índice de respuesta a la eritropoyetina (IRE) es un buen marcador de adecuación en diálisis. Nefrología 21: 606-607, 2001.
18. Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15: 1207-1211, 2000.
19. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33: 63-72, 1999.
20. MacDougall IC, Cooper A: The inflammatory and epoetin sensitivity. Nephrol Dial Transplant 17 (Supl. 1): 48-52.
21. Churchill DN, Muirhead N, Goldstein M: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant erythropoietin. J Am Soc Nephrol 4: 1809-1813, 1994.
22. Christensson AG y cols.: Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis. Nephrol Dial Transplant 16: 313-19, 2001.
23. Teruel JL y cols.: Efectos cardiovasculares de la eritropoyetina. Nefrología 13 (Supl. 4): 41-44, 1993.